Mahindra & Mahindra (M&M) shares fell 5% today to ₹2,692.75 on the BSE in early Monday trading, experiencing heavy volumes. 

At 10:06 AM, M&M was the top loser on both the BSE Sensex and Nifty 50 indices, with a 4.6% decline compared to a 0.73% dip in the benchmarks. This marks the sixth consecutive day of losses, with M&M down 13% over this period. The stock has fallen 15% from its peak of ₹3,276.30 on February 10, 2025. However, over the past year, M&M has outperformed the market, rising 52% versus the BSE Sensex’s 3.8% gain.

Mahindra Lifespace Developers Raises Funds

On February 13, Mahindra Lifespace Developers Limited (MLDL), a subsidiary of M&M, announced a ₹1,500 crore rights issue to raise funds for reducing debt and supporting future growth. M&M holds a 51.15% stake in MLDL. MLDL shares hit a 52-week low of ₹345.95, falling 49% from their 52-week high of ₹679.15 in April 2024. MLDL’s real estate footprint spans 39.44 million sq. ft. across 7 Indian cities, and the company is developing over 5,000 acres in industrial and residential clusters.

Electric Vehicle Launches and Strong Demand

In a separate announcement on February 14, M&M reported record bookings for its new electric SUVs, the XEV 9e and BE 6, which together garnered 30,179 bookings on the first day, totalling ₹8,472 crore in booking value (ex-showroom price). The XEV 9e accounted for 56% of the bookings and the BE 6 for 44%, with 73% of customers opting for the premium variant. M&M’s electric SUVs, unveiled in November 2024, have attracted significant attention, signalling rising demand for premium EVs in India. Deliveries are expected to begin in mid-March 2025, and M&M is planning to produce about 5,000 EV units per month initially.

About Mahindra & Mahindra

Mahindra & Mahindra, an Indian automobile manufacturer based in Mumbai, Maharashtra, was founded in 1945 as Mahindra & Mohammed before being renamed Mahindra & Mahindra.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Manappuram Finance shares surged over 8% on Monday after the stock was removed from the Futures and Options (F&O) ban list. The stock opened at ₹182.05 on the BSE and climbed to an intraday high of ₹193.60.

Impact of Q3 FY25 Results on Stock Performance

On February 14, Manappuram Finance shares dropped 5% to ₹183 after the company posted weak Q3 FY25 results. The decline was mainly due to challenges in its microfinance business, which faced a temporary loan disbursement ban.

The company’s consolidated net profit fell by 50% to ₹282 crore, while bad loans and provisions in the microfinance segment quadrupled to ₹473 crore. The Reserve Bank of India (RBI) had imposed the ban due to concerns over high interest rates and excessive mark-ups, which was lifted last month. The microfinance revenue declined 5% to ₹665 crore.

Future Growth Plans 

With the ban lifted, Manappuram Finance plans to gradually resume growth in the microfinance segment while shifting focus towards gold and secured non-gold loans. The company aims to expand larger-ticket gold loans and adjust interest rates in microfinance, which may impact margins.

About Manappuram Finance

Manappuram Finance is a Non-Banking Financial Company (NBFC) that offers various fund-based and fee-based services, including gold loans and money exchange. It is classified as a Systemically Important Non-Deposit Taking NBFC (NBFC-ND).

As of 11:44 AM IST on February 17, Manappuram Finance share price is trading at ₹188.32, up 5.71% (+₹10.17) for the day. The stock opened at ₹185.00, reached a high of ₹193.69, and a low of ₹183.06. The company has a market capitalisation of ₹15,940 crore, a P/E ratio of 11.33, and a dividend yield of 2.12%. Its 52-week high stands at ₹230.40, while the 52-week low is ₹138.35.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Shares of Senco Gold dropped another 15% on February 17, falling below their IPO price of ₹317. This follows a sharp 19% decline on Friday, bringing the total 2-day loss to over 30%. The stock hit a low of ₹304.55, which is 29% below its IPO listing price of ₹431. The last similar drop was in October 2023, when the stock plunged 19% in a single session.

Weak Q3 FY25 Results Impact Stock Price

Senco Gold’s net profit for Q3 FY25 declined 69% year-on-year to ₹33.5 crore, compared to ₹109.3 crore in the same period last year. Adjusted profit after tax (PAT) also fell 50.9% YoY to ₹53.7 crore.

The company attributed the decline in EBITDA and PAT margins to customs duties. However, it expects an EBITDA margin of 7%-8% going forward.

Company’s Outlook for FY25 and FY26

Suvankar Sen, MD and CEO of Senco Gold stated that customs duty and hedging costs impacted Q3 by ₹70 crore, but these costs were already accounted for in Q2 and Q3, ensuring no impact in Q4 FY25. The company forecasts 18-20% revenue growth in FY25, with an EBITDA margin of 7%. For FY26, the EBITDA margin guidance is 7-8%. While demand for studded jewellery was weak in Q3, it is showing signs of recovery in Q4.

About Senco Gold Limited

Founded in 1994, Senco Gold Limited is a nationwide jewellery retailer and the largest organised jewellery brand in Eastern India by store count.

As of Monday, February 17, Senco Gold share price are trading 8.46% lower at ₹327.35. The stock has fallen over 40% so far in 2025.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Shares of Rail Vikas Nigam Ltd (RVNL) fell 7% to ₹336.25 on February 17 after the company reported a decline in its Q3 FY25 net profit. The railway PSU posted a net profit of ₹311 crore for Q3 FY25, down 13% from ₹359 crore in Q3 FY24.

Financial Performance in Q3 FY25

RVNL’s revenue from operations fell 3% YoY to ₹4,567 crore, compared to ₹4,689 crore in Q3 FY24. Meanwhile, total expenses rose 2% to ₹4,480 crore. The company’s earnings per share (EPS) for the quarter stood at ₹1.49.

Pending Payments from KRCL

RVNL also revealed that it had incurred expenditure on a project for Krishnapatnam Railway Company Limited (KRCL), a joint venture. However, KRCL has yet to pay ₹1,441 crore, including ₹927 crore in interest, as of December 31, 2024.

Stock Performance and Market Reaction

The stock initially dropped sharply but recovered some losses to ₹347 per share, still down 4% from the previous close. Over the past month, RVNL shares have fallen nearly 18%. The stock initially surged as investors expected a higher railway capex allocation in Budget 2025 but later dropped after no such increase was announced.

About Rail Vikas Nigam Limited

Rail Vikas Nigam Limited (RVNL) is a central public sector enterprise in India that serves as the construction arm of the Ministry of Railways, focusing on project execution and transport infrastructure development.

As of 11:09 AM IST on February 17, RVNL share price is trading at ₹343.70, down 4.50% (-₹16.20). The stock opened at ₹340.00, reached a high of ₹354.80, and a low of ₹332.55. RVNL has a market capitalisation of ₹72,510 crore, a P/E ratio of 53.21, and a dividend yield of 0.61%. The stock’s 52-week high is ₹647.00, while its 52-week low stands at ₹213.05.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Several stocks, including Gillette India, Bharat Forge, Hindustan Aeronautics (HAL), NBCC (India), and Natco Pharma, will be in focus as their ex-dividend date approaches. As per BSE data, these stocks will trade ex-dividend on Tuesday, February 18, 2025, after announcing interim dividends for shareholders.

Key Dividend Stocks to Watch

Here’s the full list of companies whose shares will trade ex-dividend on Tuesday, February 18, 2025, along with their dividend announcements and record dates:

 

Understanding Ex-Dividend and Record Dates

• Ex-Dividend Date: This is the date when a stock starts trading without dividend eligibility. Investors must buy the stock before this date to qualify for the dividend payout.
• Record Date: On this day, the company finalises the list of shareholders who are eligible to receive the dividend.

These stocks may see movement in today’s trading session as investors adjust their positions ahead of the ex-dividend date.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Indian markets are expected to be impacted today. As of 7:30 AM, GIFT Nifty futures were down by 27.65 points at 22,969.

In the previous session, the Sensex dropped by 200 points (0.26%) to 75,939.21, while the Nifty50 fell by 102.15 points (0.44%) to 22,929.25.

Easy Trip Planners

Easy Trip Planners reported a 26% drop in net profit for Q3FY25 at ₹33.6 crore, down from ₹45.6 crore a year ago.

Glenmark Pharma

Glenmark Pharma posted a net profit of ₹348 crore, recovering from a ₹351 crore loss in the same quarter last year.

Reliance Industries (RIL)

Reliance Industries plans to challenge the Delhi High Court’s ruling on gas siphoning in the Krishna-Godavari basin in the Supreme Court.

Godrej Properties

Godrej Properties acquired 12 land parcels between April and December to develop housing projects worth ₹23,450 crore.

Bank of Maharashtra

Bank of Maharashtra received approval from the RBI to set up an IFSC Banking Unit in GIFT City.

SAIL (Steel Authority of India Ltd.)

SAIL plans to invest $800 million in a new rail mill.

Mahindra Lifespaces

Mahindra Lifespaces is looking to raise ₹1,500 crore through a share issue to reduce debt and fund expansion.

These developments could impact market sentiment and stock movements today.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

On February 14, 2025, the National Stock Exchange (NSE) Nifty50 ended at 22,929.25, declining by 102.15 points or 0.44%. During the session, it reached an intraday high of 23,133.7 and a low of 22,774.85. Meanwhile, the BSE Sensex slipped 199.76 points or 0.26% to settle at 75,939.21 after touching a high of 76,138.97 and a low of 75,439.64 during the day.

Here are the top gainers and losers on February 14, 2024: 

Top Gainers of the Day

• Britannia led the gainers, rising 0.95% to close at ₹4,935.00.
• ICICI Bank gained 0.81%, closing at ₹1,259.00.
• Nestlé India advanced 0.76% to settle at ₹2,194.00.
• Infosys inched up 0.53% to ₹1,853.00.
• HCL Tech gained 0.50%, ending at ₹1,711.60.

Top Losers of the Day

• Adani Ports was the biggest loser, dropping 4.63% to ₹1,060.05.
• BEL fell 4.42% to ₹250.00.
• Adani Enterprises declined 4.26%, closing at ₹2,149.00.
• Trent dropped 2.89% to ₹5,105.00.
• Grasim lost 2.69%, settling at ₹2,423.00.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

 

KNR Constructions share price traded at ₹247.85 as of 1:16 PM IST on February 14, down 4.86% (-₹12.65) for the day. The stock opened at ₹260.45, reached a high of ₹264.05, and a low of ₹246.55. The company’s market capitalisation stands at ₹6,970 crore, with a P/E ratio of 6.30 and a dividend yield of 0.10%. Its 52-week high is ₹415.40, while the 52-week low is ₹236.75.

Q3 FY25 Financial Results

The company reported an 83% YoY rise in consolidated net profit to ₹248.28 crore in Q3FY25, compared to ₹135.68 crore in Q3FY24. However, revenue fell 15% YoY to ₹848.1 crore from ₹996.1 crore. EBITDA, including other revenue, stood at ₹255.59 crore, up from ₹225.91 crore a year ago, with EBITDA margins improving to 30.1% from 22.7%.

Company Overview

KNR Constructions is a leading infrastructure development company offering EPC (engineering, procurement, and construction) services across roads, highways, irrigation, and urban water management. The company specialises in road construction, including highways, flyovers, and bridges.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

 

Pharma stocks saw a sharp decline on Friday, with the Nifty Pharma index falling 3% on the NSE after US President Donald Trump announced new reciprocal tariffs for trade partners.

Shares of Natco Pharma, Laurus Labs, Lupin, Glenmark Pharma, Granules India, Aurobindo Pharma, and Mankind Pharma dropped 4-10% in intraday trade.

At 11:26 AM, the Nifty Pharma index was the worst-performing sectoral index, down 3%, compared to a 0.67% decline in the Nifty 50. So far in 2025, the pharma index has fallen 11%, while the Nifty 50 has dropped 3.7%.

Impact of Trump’s Trade Policies

President Trump ordered his administration to consider reciprocal tariffs, potentially leading to a broader trade battle. 

During Trump’s first term, Indian pharma stocks struggled due to multiple challenges:

• US supply chain consolidation
• Regulatory issues from the FDA
• Limited product approvals
• Price controls and FDC bans in India

While these problems weren’t caused by Trump directly, his focus on US manufacturing, tariff hikes, and drug cost reduction impacted pharma stocks.

Natco Pharma Slumps 11% on Weak Q3 Results

Natco Pharma share price fell 11% to ₹872.65, continuing its 29% decline over 2 days after weak Q3FY25 results.

• Q3 profit dropped 37.8% YoY to ₹132.4 crore
• Sequentially, profit fell 80% from ₹676.5 crore in Q2FY25
• Revenue declined 18% YoY and 54.6% QoQ to ₹651 crore
• EBITDA margin shrank to 33% from 38.3% in Q3FY24 and 60.5% in Q2FY25

Revenue from export formulations dropped 52.8% YoY and 76.4% QoQ to ₹285.8 crore. Natco remains vulnerable to US market conditions and currency fluctuations.

Concord Biotech Plunges 16% on Flat Revenue

Concord Biotech share price tumbled 16% to ₹1,777.70 after reporting weak Q3FY25 earnings:

• Profit fell 2% YoY to ₹75.92 crore
• Revenue remained flat at ₹244.22 crore vs. ₹240.80 crore in Q3FY24
• EBITDA margin dropped to 40.1% from 44%

The company said revenue was affected by customer procurement patterns and delayed orders. However, it expects growth in its API and formulation businesses due to new products, customer additions, and increased market share.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.